PACIFIC-9
14 Dec 2022
PACIFIC-9
NCT05221840
A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
AstraZeneca
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Advanced |
Anticipated Start Date | 2022-02-07 |
Anticipated End Date | 2026-05-29 |
Hospital | Lyell McEwen Hospital |
---|---|
Clinical Trial Coordinator | Andy Phay |
Andy.Phay@sa.gov.au | |
Phone | 08 8282 0833 |
Principal Investigator | Dr Dainik Patel |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs